Glaxo Diabetes Drug Data Revealed Amid Hostile Takeover

GlaxoSmithKline Plc will reveal detailed results today on an experimental treatment for diabetes that’s part of the reason for a $2.6 billion hostile takeover bid for Human Genome Sciences Inc., its partner on the drug.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.